FindTrial
Sign In

Changes of Cystatin SN in serum of patients with pancreatic adenocarcinoma (PAAD) and its clinical value

Changes of Cystatin SN in serum of patients with pancreatic adenocarcinoma (PAAD) and its clinical value

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200058697
Enrollment
Unknown
Registered
2022-04-14
Start date
2022-04-01
Completion date
Unknown
Last updated
2024-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

Normal group:None
Acute pancreatitis group:None
Chronic pancreatitis group:None
Pancreatic cancer group:None

Sponsors

The Second Affiliated Hospital of Kunming Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years old, male or female; 2. The patient can understand and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant women; 2. Patients who are participating in other clinical trials; 3. Physicians think that they are not suitable for inclusion (such as critical illness).

Design outcomes

Primary

MeasureTime frame
Cystatin-SN (CST1);—

Countries

China

Contacts

Public ContactChunman Li

The Second Affiliated Hospital of Kunming Medical University

lcmaxxm@163.com+86 15887036810

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026